Design, synthesis, and biological evaluation of (2R,αS)-3,4-dihydro- 2-[3-(1,1,2,2-tetrafluoroet-hoxy)phenyl]-5-[3-(trifluoromethoxy)-phenyl] -a-(trifluoromethyl)-1(2H)-quinolineethanol as potent and orally active cholesteryl ester transfer protein inhibitor

Journal of Medicinal Chemistry

Volumn 52, Issue 6, 2009, Pages 1768-1772

  Kuo, Gee Hong ^a   Rano, Thomas ^a   Pelton, Patricia ^a   Demarest, Keith T ^a   Gibbs, Alan C ^a   Murray, William V ^a   Damiano, Bruce P ^a   Connelly, Margery A ^a  

^a Johnson Pharmaceutical Research and Development LLC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3,4 DIHYDRO 2 [3 (1,1,2,2 TETRAFLUOROETHOXY)PHENYL] 5 [3 (TRIFLUOROMETHOXY)PHENYL]ALPHA (TRIFLUOROMETHYL) 1(2H) QUIOLINEETHANOL; CHOLESTEROL ESTER TRANSFER PROTEIN INHIBITOR; TORCETRAPIB; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG DESIGN; DRUG EFFICACY; DRUG SCREENING; DRUG SYNTHESIS; HAMSTER; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; RAT;

ADMINISTRATION, ORAL; ANIMALS; CHOLESTEROL ESTER TRANSFER PROTEINS; CRICETINAE; DIETARY FATS; DRUG DESIGN; HUMANS; MACACA FASCICULARIS; MAGNETIC RESONANCE SPECTROSCOPY; MICE; QUINOLINES; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION;

EID: 64349124065     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm801319d     Document Type: Article

References (22)

1. Bays, H.; Stein, E. A. Pharmacotheraphy for dyslipidemia-current therapies and future agents. Expert Opin.pharmacother. 2003, 4 (11), 1901-1938.
2. Eckel, R. H.; Grundy, S. M.; Zimmet, P. Z. The metabolic syndrome. Lancet 2005, 365, 11415-11428.
3. Baigent, C.; Keech, A.; Kearney, P. M.; Blackwell, L.; Buck, G.; Pollicino, C.; Kirby, A.; Sourjina, T.; Peto, R.; Collins, R.; Simes, J. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90056 participants in 14 randomised trials of statins. Lancet 2005, 366, 1267-1278.
4. Evans, M.; Roberts, A.; Davies, S.; Rees, A. Medical lipid-regulating therapy: Current evidence, ongoing trials and future developments. Drugs 2004, 64, 1181-1196.
5. Gordon, T.; Castelli, W. P.; Hjortland, M. C.; Kannel, W. B.; Dawber, T. R. High density lipoprotein as a protective factor against coronary heart disease. The Framingham study. Am. J. Med 1977, 62, 707-714.
6. Gordon, D. J.; Probstfield, J. L.; Garrison, R. J.; Neaton, J. D.; Castelli, W. P.; Knoke, J. D., Jr.; Bangdiwala, S.; Tyroler, H. A. High density lipoprotein cholesterol and cardiovascular disease. Circulation 1989, 79, 8-15.
7. Sikorski, J. A. Oral cholesteryl ester transfer protein (CETP) inhibitors: a potential new approach for treating coronary artery disease. J. Med. Chem. 2006, 49 (1), 1-22.
8. Watts, G. F. The yin and yang of cholesteryl ester transfer protein and atherosclerosis. Clin. Sci. 2002, 103, 595-597.
9. Barter, P. J.; Brewer, H. B., Jr.; Chapman, M. J.; Hennekens, C. H.; Rader, D. J.; Tall, A. R. Cholesteryl ester transfer protein: a novel target for raising HDL and inhibiting atherosclerosis. Arterioscler. Thormb. Vasc. Biol. 2003, 23, 160-167.
10. McPherson, R.; Mann, C. J.; Tall, A. R.; Hogue, M.; Martin, L.; Milne, R. W.; Marcel, Y. L. Plasma concentration of cholesteryl ester transfer protein in hyperlipoproteinemia. Arterioscler. Thromb. Vasc. Biol. 1991, 11, 797-804.
11. Barter, P. J.; Caulfield, M.; Eriksson, M.; Grundy, S. M.; Kastelein, J. J. P.; Komajda, M.; Lopez-Sendon, J.; Mosca, L.; Tardif, J. C.; Waters, D. D.; Shear, C. L.; Revkin, J. H.; Buhr, K.; Fisher, M. R.; Tall, A. R.; Brewer, B. Effects of torcetrapib in patients at high risk for coronary events. N. Engl J. Med. 2007, 357, 2109-2122.
12. (a) Shinkai, H.; Maeda, K.; Yamasaki, T.; Okamoto, H.; Uchida, I. Bis(2-(acylamino)-phenyl)disulfides, 2-(acylamino)benzenethiols, and S-(2-(acylamino)-phenyl)-alkanethioates as novel inhibitors of cho-lesteryl ester transfer protein. J. Med. Chem. 2000, 43, 3566-3572.
13. (b) Kontush, A.; Guerin, M.; Chapman, M. J. Spotlight on HDL-raising therapies: insights from the torcetrapib trials. Nat. Clin. Pract. Cardiovasc. Med. 2008, 5, 329-336.
14. Vergeer, M.; Kastelein, J. J. P. Anacetrapib: new hope for cholesteryl ester transfer protein inhibitors in the treatment of dyslipidemia. Nat. Clin. Pract. Cardiovasc. Med. 2008, 5, 302-303.
15. van den Hoogenband, A.; Lange, J. H. M.; Iwema-Bakker, W. I.; den Hartog, J. A. J.; van Schaik, J.; Feenstra, R. W.; Terpstra, J. W. An efficient one-pot synthesis of novel 4-aryl-1-methyloxindoles. Tetrahedron Lett. 2006, 47 (26), 4361-4364.
16. Fukuyama, T.; Jow, C.-K.; Cheung, M. 2-and 4-Nitrobenzenesulfona-mides: Exceptionally versatile means for preparation of secondary amines and protection of amines. Tetrahedron Lett. 1995, 36 (36), 6373-6374.
17. Yamada, K.; Kubo, T.; Tokuyama, H.; Fukuyama, T. A mild copper-mediated intramolecular amination of aryl halides. Synlett 2002, 2, 231-234.
18. Ramachandran, P. V.; Gong, B.; Brown, H. C. Chiral synthesis via organoboranes. 40. Selective reductions. 55. A simple one-pot synthesis of the enantiomers of (trifluoromethyl)oxirane. A general synthesis in high optical purities of a-trifluoromethyl secondary alcohols via the ring-cleavage reactions of the epoxide. J. Org. Chem. 1995, 60, 41-46.
19. Rano, T.; Kuo, G.-H.; Sieber-McMaster, E.; Demarest, K. T.; Pelton, P.; Wang, A. 1,2,3,4-Tetrahydro-quinoline derivatives as CETP inhibitors. U.S. Pat. Appl. Publ. US 2007265304 A1 20071115, 2007.
20. Reinhard, E. J.; Wang, J. L.; Durley, R. C.; Fobian, Y. M.; Grapperhaus, M. L.; Hickory, B. S.; Massa, M. A.; Norton, M. B.; Promo, M. A.; Tollefson, M. B.; Vernier, W. F.; Connolly, D. T.; Witherbee, B. J.; Melton, M. A.; Regina, K. J.; Smith, M. E.; Sikorski, J. A. Discovery of a simple picomolar inhibitor of cholesteryl ester transfer protein. J. Med. Chem. 2003, 46, 2152-2168.
21. Veber, D. F.; Johnson, S. R.; Cheng, H. Y.; Smith, B. R.; Ward, K. W.; Kopple, K. D. Molecular properties that influence the oral bioavail-ability of drug candidates. J. Med. Chem. 2002, 45, 2615-2623.
22. Clark, R. W.; Ruggeri, R. B.; Cunningham, D.; Bamberger, M. J. Description of the torcetrapib series of cholesteryl ester transfer protein inhibitiors, including mechanism of action. J. Lipid Res. 2006, 47, 537-552.